[Chemotherapy-induced peripheral neuropathy: characteristics, diagnosis and treatment].
Longer remissions and better overall survival rates can be achieved with the introduction of new, effective treatments and targeted therapies in the past 1-2 decades, however, the incidence of side effects is also increasing parallelly. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially debilitating side effect due to peripheral somatic or autonomic nerve dysfunction. CIPN becomes increasingly important, as it affects patients' quality of life, and it is very often a dose limiting factor with the potential for reduced treatment efficacy. The pathomechanism, diagnosis, prevention and treatment possibilities are described in this review with special attention to the different groups of drugs.
I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. istildi78@gmail.com.
Ildikó
I
Istenes
I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. istildi78@gmail.com.
Zsolt
Z
Nagy
I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary. istildi78@gmail.com.
Judit
J
Demeter
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D009369:Neoplasms / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D011788:Quality of Life
D000970:Antineoplastic Agents